Alexion has boosted AstraZeneca’s rare disease expertise while the company has experienced success in oncology and COVID-19.

AstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States.

Monday morning, Innate Pharma announced that a planned futility interim analysis of the INTERLINK-1 Phase III trial sponsored by AstraZeneca failed to hit a pre-defined threshold for efficacy. This follows AstraZeneca’s Q2 report released on July 29 that included several other drugs and trials the company is axing.